Tybourne Capital Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.46M | Buy |
4,095,000
+395,000
| +11% | +$912K | 27.39% | 2 |
|
|
2025
Q1 | $5.14M | Hold |
3,700,000
| – | – | 21.83% | 2 |
|
|
2024
Q4 | $6.4M | Hold |
3,700,000
| – | – | 1.61% | 16 |
|
|
2024
Q3 | $7.44M | Hold |
3,700,000
| – | – | 2.08% | 11 |
|
|
2024
Q2 | $8.29M | Hold |
3,700,000
| – | – | 1.69% | 14 |
|
|
2024
Q1 | $10.6M | Hold |
3,700,000
| – | – | 1.82% | 16 |
|
|
2023
Q4 | $6.55M | Buy |
3,700,000
+2,200,000
| +147% | +$3.89M | 0.98% | 19 |
|
|
2023
Q3 | $4.74M | Hold |
1,500,000
| – | – | 0.66% | 18 |
|
|
2023
Q2 | $992K | Hold |
1,500,000
| – | – | 0.11% | 32 |
|
|
2023
Q1 | $1.2M | Hold |
1,500,000
| – | – | 0.12% | 25 |
|
|
2022
Q4 | $3.39M | Buy |
1,500,000
+1,000,000
| +200% | +$2.26M | 0.34% | 26 |
|
|
2022
Q3 | $965K | Hold |
500,000
| – | – | 0.09% | 26 |
|
|
2022
Q2 | $1.86M | Hold |
500,000
| – | – | 0.13% | 27 |
|
|
2022
Q1 | $3.26M | Hold |
500,000
| – | – | 0.19% | 28 |
|
|
2021
Q4 | $5.83M | Hold |
500,000
| – | – | 0.17% | 25 |
|
|
2021
Q3 | $9.31M | Hold |
500,000
| – | – | 0.23% | 20 |
|
|
2021
Q2 | $10.6M | Hold |
500,000
| – | – | 0.22% | 24 |
|
|
2021
Q1 | $10.2M | Hold |
500,000
| – | – | 0.22% | 30 |
|
|
2020
Q4 | $13.3M | Hold |
500,000
| – | – | 0.28% | 28 |
|
|
2020
Q3 | $11.2M | Buy |
+500,000
| New | +$11.2M | 0.28% | 29 |
|